Cure Ventures

Cure Ventures, based in Boston, Massachusetts, is a life sciences venture capital firm founded in 2021. The firm focuses on early-stage investments in biotechnology, particularly in new therapeutics. They aim to drive groundbreaking curative technologies from concept to clinical success. Cure Ventures closed their inaugural fund at $350 million, indicating substantial resources dedicated to their mission. The investment strategy at Cure Ventures emphasizes genetic validation to guide drug development, thus increasing the probability of success while reducing the cost of failure. They use a seed funding model to de-risk scientific ventures, with plans to co-lead Series A and B rounds for promising companies. Their hands-on approach involves embedding Cure operators within portfolio companies to assist with day-to-day decision making​. The team at Cure Ventures includes co-founders Richard Lim, David Fallace, and Lou Tartaglia, who bring extensive experience from successful biotech firms like Juno Therapeutics and Agios Therapeutics. Their backgrounds provide a strong foundation for supporting startups through scientific and operational challenges. Notable investments by Cure Ventures include Clasp Therapeutics, Kenai Therapeutics, and Tasca Therapeutics, reflecting their focus on innovative biotechnological solutions. Startups looking to approach Cure Ventures should highlight their potential for breakthrough therapies and be prepared for an intensive, collaborative partnership aimed at achieving significant medical advancements.